SCHEMBL6502650

SCHEMBL6502650

C=CCN1CCN(c2ccc(NC(=O)C3=C(c4ccc(C)cc4)CCCC3)cc2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.47
NPC1 O15118 7/20 0.47
RAB9A P51151 7/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
KMT2A Q03164 3/20 0.47
MEN1 O00255 2/20 0.47
KDM4E B2RXH2 2/20 0.47
MCL1 Q07820 2/20 0.47
LMNA P02545 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
GFER P55789 1/20 0.44
ALDH1A1 P00352 4/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
GLA P06280 2/20 0.43
TP53 P04637 2/20 0.43
PKM P14618 1/20 0.43
MAPK1 P28482 1/20 0.43
CA1 P00915 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490778 0.88 MAPKAPK2 (0.46) MAPTKDM4ELMNAALDH1A1CA1
SCHEMBL6498772 0.83 MAPT (0.58) MAPTRAB9ASMN1; SMN2KMT2AKDM4E
SCHEMBL6499989 0.81 NPC1 (0.53) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL6499900 0.81 DRD2 (0.46) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL6499147 0.81 MAPT (0.46) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL6504210 0.78 KMT2A (0.45) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL6492454 0.78 MAPT (0.41) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL6490476 0.78 MEN1 (0.42) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL6488746 0.78 MAPT (0.60) MAPTNPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL6491504 0.77 FAAH (0.49) MAPTRAB9ASMN1; SMN2KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 MAPT 4202/4885NPC1 100/4885RAB9A 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.